Evogene Schedules First Quarter 2024 Financial Results Release
Evogene Schedules First Quarter 2024 Financial Results Release
Zoom conference call scheduled for 9:00 AM ET
Zoom 電話會議定於美國東部時間上午 9:00
REHOVOT, Israel, May 9, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2024, on Thursday, May 23, 2024.
以色列雷霍沃特，2024 年 5 月 9 日 /PRNewswire/-- Evogene Ltd。納斯達克股票代碼：EVGN）（TASE: EVGN）是一家旨在徹底改變生命科學產品發現和開發的領先計算生物學公司，今天宣佈將在上線發佈2024年第一季度的財務業績 2024年5月23日，星期四。
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
當天晚些時候，公司管理層將舉辦 美國東部時間上午 9:00 召開電話會議，討論結果 （以色列時間下午 4:00）。
To join the conference, please register in advance:
要參加會議，請提前註冊：
The entire conference will be available online on the company's website a few days after.
幾天後，整個會議將在公司的網站上在線公佈。
About Evogene:
關於 Evogene：
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene Ltd.（納斯達克股票代碼：EVGN，TASE：EVGN）是一家利用大數據和人工智能的計算生物學公司，旨在通過利用尖端技術來提高成功概率，同時減少開發時間和成本，從而徹底改變基於生命科學的產品的開發。
Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene 建立了三種獨特的技術引擎- 微升壓 AI， ChemPass AI 和 生成器人工智能。每個技術引擎都專注於發現和開發基於以下核心成分之一的產品：微生物（MicroBoost）、小分子（ChemPass AI）和遺傳元素（生成器人工智能)。
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:
Evogene使用其技術引擎通過戰略伙伴關係和合作開發產品，其四家子公司包括：
- Biomica Ltd. () - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
- Lavie Bio Ltd. () - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI;
- AgPlenus Ltd. () - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
- Casterra Ag Ltd. () - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI.
- Biomica 有限公司 ()-開發和推進基於微生物組的新型療法，用於治療人類疾病 微增強人工智能;
- Lavie Bio 有限公司 () - 開發和商業推進基於微生物組的農業生物製劑，由 微增強人工智能;
- agPlenus 有限公司 ()-開發下一代農業化學品，以實現有效和可持續的作物保護 ChemPass AI;
- Casterra Ag 有限公司 ()-在工業規模上爲生物燃料和其他行業開發和銷售具有高產量和高品位含油量的優質蓖麻種子品種 生成器人工智能。
For more information, please visit: .
欲了解更多信息，請訪問：。
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
[email protected]
Tel: +972-8-9311901
聯繫人
雷切爾·波美蘭茲·格伯
Evogene 投資者關係主管
[電子郵件保護]
電話：+972-8-9311901
Logo:
徽標：
SOURCE Evogene
來源 Evogene
譯文內容由第三人軟體翻譯。